Hyman Phelps and McNamara
 
Firm Publications
 

A Warning Letter on FDA's Expansive Interpretation of Its Facilities - Inspection Authority
March 13, 2015

In this Legal Backgrounder published by the Washington Legal Foundation, HPM authors write a “Warning Letter” to FDA-regulated drug establishments regarding FDA’s inspection practices. This article addresses several of the unresolved questions regarding FDA’s inspection authority and aggressive inspection practices, as discussed in FDA’s Guidance for Industry: Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection (2014).

Click here to view the link

If you have any questions regarding the above information, please contact:
James P. Ellison (202) 737-4294 jellison@hpm.com
Anne K. Walsh (202) 737-4592 awalsh@hpm.com
Andrew J. Hull (202) 737-4296 ahull@hpm.com